The Bruton's tyrosine kinase inhibitor tolebrutinib is reportedly the first agent to show benefit in patients with nonrelapsing secondary progressive MS.
As the world of technology advances, programming competitions are becoming increasingly popular. They offer not just a platform to showcase coding skills but al ...